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Abstract
Background:
Clear cell variant in ependymal tumors is rare. We aimed to compare the features and outcome of the
World Health Organization (WHO) Grade 3 ependymal tumors with clear cells to the WHO Grade 3
classic anaplastic ependymoma (AE).
Materials and Methods:
A retrospective cohort study conducted at the Department of Neurosurgery, Aga Khan University,
Pakistan, from 2003 to 2013. The medical records and radiology of patients with proven histopathology
were reviewed. The analysis was done on SPSS 20.
Results:
Nine cases of clear cell variant and 23 cases of classic AE were found, both of which combined
equated to 4% of the total tumor burden in 11 years. The median age of clear cell ependymoma (CCE)
and AE were 49 and 37 years, respectively. Presenting symptoms included headache in 66% of CCE
and 63% in AE, raised intracranial pressure accounting for 33% of CCE and 54% of AE, dizziness in
22% CCE and 39% AE, while seizures presented equally in both. Supratentorial location was observed
in 77% CCE and 48% AE. Both showed hypointense signals on T1-weighted images of magnetic
resonance imaging (MRI) while T2-weighted images showed hyperintensity in all cases of CCE but
only 80% of AE. MRI characteristics such as the presence of cystic component were found in 89% of
CCE and 68% of AE, necrosis in 33% CCE, and 22% AE, hemorrhagic in 22% CCE and 9% AE, and
equivalent contrast enhancement. Gross total resection was achieved in 5 (55%) patients of CCE,
compared to 6 (26%) patients in AE. Subtotal resection was done in 4 (44%) patients of CCE and 15
(65%) patients of AE. Radiotherapy was given to 5 (55%) patients of CCE and 12 (52%) patients of
AE. Recurrence was observed in 77% cases of CCE and 70% of AE, with metastasis in 29% of AE and
in only one patient of CCE. Repeat surgery was done in 3 (33%) cases of CCE and 8 (35%) cases of
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AE. Median progression-free survival and overall survival were 9 and 13 months, respectively, in CCE
while 14 and 18 months, respectively, for AE.
Conclusion:
Clear cells in the WHO Grade 3 ependymal tumors are found mainly in a comparatively older adult
population with a predilection for supratentorial location and are more aggressive in behavior with
poorer outcome than AE.
Keywords: Anaplastic ependymoma, clear cell ependymoma, progression-free survival, recurrence,
rosettes
Introduction
Ependymal tumors are relatively rare glial tumors arising from ependymal cells in the brain which
constitute only 2%–8% of the central nervous system (CNS) malignancies.[1] The revised World
Health Organization (WHO) classification of brain tumors in 2007 broadly classified ependymomas
into three histological grades. Myxopapillary ependymomas and subependymomas being classified as
Grade 1 tumor. Clear cell, papillary, cellular, and tancytic subtypes considered as Grade 2 tumors. And
the anaplastic variant being considered as a Grade 3 tumor.[2] In contrast to other glial tumors, the
histological grade of ependymal tumors has conflicting significance as a prognostic and predictive
marker.[3,4] In addition to the histological grade, the site of the tumor and the age at the initial
diagnosis has been a pertinent prognostic factor for survival in patients with ependymomas.[5] In
recent years, classification of ependymomas based on tumor location such as supratentorial
ependymomas, posterior fossa ependymomas, and spinal ependymomas has highlighted an in-depth
insight as one of the most important determinants of outcome.
Clear cell ependymoma (CCE) is a rare, diagnostically challenging and aggressive variant of
ependymomas, with acceptance as a separate entity in the WHO classification of tumors only in 1993.
[6] Ever since it was first described in 1983,[7] the literature has been scarce on this entity. Although
CCE is mostly supratentorial in location, other sites mentioned in the literature include cervical and
thoracic spinal cord, brain surface, medulla, fourth ventricle, and cerebellum.[8,9,10,11,12,13,14,15]
Histologically, CCE tumor cells display classic ependymal rosettes and perivascular pseudorosettes
with an oligodendroglioma (ODG) such as appearance having a clear perinuclear halo and positive
immune reactivity to glial fibrillary acidic protein and epithelial membrane antigen.[2,10,11] In
comparison, anaplastic ependymoma (AE) display increased cell density, brisk mitotic activity,
microvascular proliferation, and palisading necrosis.[16] The similar gene expression patterns of Grade
2 and Grade 3 malignancies highlight progression of Grade 2 into Grade 3 ependymomas.
CCE although being a variant of Grade 2, ependymoma has most of the published series to date
highlighting the presence of clear cells more in histologically proven AE Grade 3 than Grade 2.[14]
The elusive histological criteria with no cutoffs being defined for mitosis or percentage of tumor
depicting increased cellularity, grading of ependymoma into Grades 2 and 3 remains controversial, and
unreliable in predicting the outcome.[16] Hence, it is important to distinguish this entity from other
pathologies which may pose a diagnostic challenge, such as ODG, central neurocytoma, clear cell
carcinoma, and hemangioblastoma, especially as the treatment and prognosis of each differ
significantly. Surgery remains the mainstay treatment for ependymal tumor. It is desirable to attempt a
gross total resection (GTR) where possible, without causing neurological deficits with concomitant
radiotherapy, as postoperative radiotherapy improves survival. A clear advantage of augmenting
radiotherapy with chemotherapy is yet to be established.
Therefore, we aimed to compare the frequency, clinical, radiological, surgical and histopathological
aspects, with outcome such as progression-free survival (PFS) and overall survival (OS) of the WHO




Grade 3 ependymal tumors with clear cells to the WHO Grade 3 classic AE.
Materials and Methods
This was a retrospective cohort study conducted at the Department of Neurosurgery, Aga Khan
University Hospital, Karachi, Pakistan. Institutional approval was obtained from the Ethics Review
Committee, and informed consent was acquired from the enrolled patients. Medical Records of all the
cases of primary CNS tumors operated from January 2003 to December 2013 were retrieved and
reviewed from the electronic database of the hospital using International Classification of Diseases
codes 190.0-191.9.
Data were systematically collected on a structured pro forma, which included patient demographics,
presenting complaints, Karnofsky Performance Score (KPS), radiology, course of treatment, including
surgery, adjuvant therapy (radiotherapy [RXT] and chemotherapy [CMT]), PFS, and recurrence as
suggested by interval 3 monthly magnetic resonance imaging (MRI) of the brain and OS.
Information about aforementioned aspects was obtained from patient's initial outpatient department
notes, initial assessment forms, progress notes, operative notes retrieved through medical record office,
and telephonic calls to patients/attendants where applicable. MRI of the brain was reviewed on picture
archiving and communication system of the hospital for tumor location, initial size, and features
specific to tumors such as contrast enhancement, appearance on T1- and T2-weighted images, and
associated characteristics such as the presence of cystic, hemorrhagic, or necrotic areas were obtained.
The histopathology slides were retrieved and reviewed by a single consultant histopathologist of all the
cases showing Grade 3 ependymal tumors, including classic AE and the clear cell variant.
GTR was defined as excision of more than 95% of tumor, and subtotal resection (STR) was defined as
excision of <95% tumor.
Descriptive analysis was done using SPSS version 20 (IBM). Median was calculated for continuous
variables, with frequencies and proportions being calculated for categorical variables. Survival analysis
was done using log-rank test and Kaplan–Meier curves, with hazard ratio being calculated by logistic
regression.
Results
For the eleven-year period starting January 2003 to December 2013, surgery was done on 677 cases of
primary intracranial tumors at Aga Khan University Hospital. Seven percent of these cases constituted
as ependymal tumors, of which 4% were Grade 3 ependymal tumors, in which 23 cases were classic
AE, whereas nine cases were Grade 3 ependymal tumors with clear cells.
The male-female ratio of CCE tumors was 6:3 whereas that of AE tumors was 10:13. The median age
was 49 years for CCE and 37 years for AE. The age range for CCE was from 24 to 72 years while 3
months to 75 years for AE. Hence, a few pediatric cases reported in AE while none in CCE.
The majority of patients presented with headache as the most common complaint, with 66% in CCE
and 63% in AE, followed by features of raised intracranial pressure (ICP) – 54% in AE as compared to
33% in CCE. Dizziness/vertigo was found more in AE with 39% as compared to 22% of CCE, with
seizures overlapping in both groups. The presenting KPS was similar in the two groups. These results
are summarized in Table 1.
Table 1
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Comparison of Patient demographics, Presenting Symptoms and Kamofsky Performance Score
While most of the CCE tumors were supratentorial in location, AE was found to be equally distributed
in supratentorial and infratentorial locations. Within CCE, the parietal lobe was the most common
location, followed by temporoparietal lobe. Although temporoparietal lobe was the most occupied site
by AE, they were also distributed in occipital, cerebellar, and intraventricular regions.
When looking at T1-weighted images on MRI, we found that both CCE and AE showed hypointense
signals. While on T2-weighted images on MRI, all the cases of CCE showed hyperintense signals,
whereas 80% of the AE showed hyperintense signals, alongside 13% showing up as iso-hyperintense.
These results are summarized in Table 2.
Table 2
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Comparison of Tumor Location, Distribution and MRI Features
The National Comprehensive Cancer Network USA clinical practice guidelines in oncology for the
treatment of adult intracranial ependymoma were followed,[17] which include GTR whenever possible,
followed by MRI spine for metastasis to cauda equina if histopathology was suggestive of AE Grade 3,
followed by external beam radiation therapy (EBRT) 54–59.4 Gy, in 1.8–2.0 Gy fractions. In case of
recurrence, reresection was performed if resectable followed by EBRT if no prior RXT was given. In
case if prior RXT was given, then consideration was given to reirradiation or CMT. In our series, GTR
could be achieved in 5 (55%) cases of CCE and 6 (26%) cases of AE while STR was done in 4 (44%)
4/25/2018 Prognostic Implications of Histological Clear Cells in High-Grade Intracranial Ependymal Tumors: A Retrospective Analysis from a Tertiar…
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898097/ 6/12
cases of CCE and 15 (65%) cases of AE. A biopsy was performed in two cases of AE. Postsurgical
adjuvant therapy with RXT was given to 5 (55%) cases of CCE and 12 (52%) cases of AE, while CMT
(temozolomide) alongside RXT was given to 3 (33%) cases of CCE and 5 (22%) cases of AE. One
CCE patient refused further treatment, while 6 patients of AE were lost to follow-up. Recurrence
occurred in 77% (7/9) of CCE and 70% (12/17) of AE. Repeat surgery was performed in 3 out of 7
patients with CCE as compared to 8 out of 12 patients with AE. Metastasis was present in 5 (29%)
cases of AE, whereas in only one patient with CCE.
Histopathological slides of both groups with specific characteristics are highlighted in Figure 1.
Figure 1
Histopathological slides of the tumors. (a) Anaplastic ependymoma in low magnification showing
perivascular pseudorosettes and true rosettes, alongside necrosis. (b) Anaplastic cells showing high mitotic
activity. (c) Clear cell ependymoma showing perivascular pseudorosettes – there is oligodendroglioma like
clear cell ependymoma. (d) Glial fibrillary acidic protein staining in anaplastic ependymoma, with Ki-67
showing high proliferative index
The PFS for CCE was 9 months, ranging between 3 and 28 months, while 14 months for AE, ranging
between 15 days and 60 months. The OS was 13 months for CCE, ranging between 3 and 41 months,
while 18 months for AE, ranging between 1 and 60 months. Survival analysis with respect to age was
statistically significant (P < 0.05) for CCE patients who were younger had better survival as compared
to patients who were older than 55 years. Similarly in AE, although the pediatric cases were censored,
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statistical significance (P < 0.017) revealed that younger patients had a better prognosis as compared to
the older patients [Figure 2].
Figure 2
Survival with respect to age
Survival with respect to the extent of resection was not statistically significant (P = 0.14); however, it
showed GTR had a better prognosis [Figure 3a]. Survival analysis of the two histopathologies showed
that CCE had a 1.86 times worse prognosis than AE [Figure 3b]. Survival with respect to recurrence
was statistically significant (P < 0.03) highlighting that patients who had recurrence had a worse
prognosis [Figure 4a], while survival with respect to postresection RXT for AE was significant (P <
0.05) showing that patients who underwent RXT had a better prognosis, whereas in patients with CCE
it was not significant (P = 0.1) [Figure 4b].
Figure 3
Survival analysis with respect to (a) extent of resection and (b) histopathology




Survival analysis with respect to (a) recurrence and (b) radiotherapy
Discussion
CCE is designated as Grade 2 ependymal tumor, having a predilection for the supratentorial
compartment, occurring predominantly in young patients.[18] In contrast to the WHO classification
designating CCE as Grade 2, we have 9 out of 32 cases demonstrating the ependymal clear cells in AE
Grade 3 instead of ependymoma Grade 2 – also, previously highlighted in the literature.
[10,19,20,21,22,23]
The median age of our series for CCE was 49 years (age range 24–72 years) and for AE was 37 years
(age range 3 months – 75 years). We found comparable cohorts with similarity to our age group,
reported by Kawano et al.,[7] Min and Scheithauer[24] and in a few other case reports.[9,15,25,26]
However, the two biggest cohorts on the subject were conducted by Fouladi et al.[10] and Rickert et
al.,[23] who have reported their work in pediatric age group, alongside others.[22,27,28] The male
predominance as previously reported was also supported by our series for CCE with a male-female
ratio of 2:1, but for AE, a female shift was observed.
The clinical presentation of our groups was more or less similar with a slight predominance of features
of raised ICP and dizziness being reported more so in AE patients as compared to CCE patients, who
followed the clinical trend previously reported in studies.[10,24] The primary tumor site highlighted in
literature was supratentorial[10,24] although occasional occurrence at other sites including cerebellum,
medulla oblongata, and fourth ventricle have also been described.[7,9,11] Our study complimented
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with similar results, especially in CCE group, however, in the AE patients, we found equal distribution
in supratentorial and infratentorial locations.
Radiologically, Fouladi et al.[10] demonstrated most cases to be isointense on both T1- and T2-
weighted images, while Hayashi et al.[27] showed hypo- to iso-intense on T1 and hyperintense on T2-
weighted images of MRI. In our study, both CCA and AE showed hypointense signal on T1, while on
T2-weighted images, all cases of CCE showed hyperintense signals, but only 80% of AE showed
hyperintense signals with 13% accounting for iso- to hyper-intense signals. Associated enhancement,
calcification, necrosis, cystic areas, and mass effect have also been reported.[7,10,15,24,27] In our
study, both CCE and AE showed enhancement in 90% cases, with necrosis and hemorrhage more
pronounced in CCE with 33% and 22%, respectively, as compared to 22% and 9%, respectively for
AE. The cystic component was slightly more prevalent in CCE patients than AE patients while both
had equal distribution with respect to solid areas.
With no defined WHO criteria, histological features of CCE varies from focal to diffuse,[10,23]
alongside a description of perivascular pseudorosettes with the absence of true rosettes, and ependymal
canals being reported.[6,11] In addition, the presence of oligodendroglioma (ODG) like clear cells
being present in AE Grade 3 rather than ependymoma Grade 2 has been extensively reported.
[10,19,20,21,22,23,29] MIB 1 (ki-67) index has been described the pertinent prognostic factor for
defining anaplasia in ependymoma.[30] These findings were consistent with our series.
The median PFS of our study was 9 and 14 months postsurgery for CCE and AE, respectively, while
median OS postsurgery was 13 months for CCE and 18 months for AE. These results were statistically
different from the ones previously reported. Armstrong et al.[31] reported a PFS and OS of 18 months
and 67 months, respectively, for adult Grade 3 ependymal tumors. For CCE, Rickert et al.[23] reported
a mean survival of >52 months and Fouladi et al.[10] A 5-year PFS was 34% ± 20% and OS 75% ±
19%. None of our patients survived post 5 years. To our comparison are two case series. Foremost,
reported for the first time from Pakistan, in our previous work on ependymal tumors with ODG like
clear cells,[29] we demonstrated a median PFS and OS of 8 and 10 months, respectively and second,
Jain et al.[20] from India reported three cases with one patient lost to follow-up at 4 months and the
other two dying of disease at 21 and 24 months, respectively. Thus, suggesting a more aggressive
nature of the tumor in this part of the world – Pakistan and India.
Among the patient-related prognostic factors that we identified, age <55 years had a positive impact on
survival analysis in both CCE and AE – being consistent with those already reported.[32,33] The extent
of surgery has been reported as one of the most significant predictors of outcome for intracranial
ependymomas,[4,32] with GTR being significantly associated with better PFS and OS.[33] Survival
with respect to the extent of resection was not significant for our series; however, GTR did show a
better prognosis. In addition, recurrence was associated with a worse prognosis, with metastasis
accounting for 29% of AE patients but only one patient of CCE. Postoperative irradiation has been
reported to significantly improve local control,[34,35] with Rogers et al.[34] recommending the use of
postoperative RXT regardless of the extent of surgical resection. Our series highlighted better
prognosis with RXT in patients with AE, with no meaningful significance for patients with CCE.
Survival analysis of the two histopathologies highlighted the presence of clear cells in intracranial
high-grade ependymal tumors being 1.8 times more hazardous on OS.
Our limitation was a small sample size owing to the rare presentation of this tumor, a retrospective
study design, a single institution data, involvement to multiple neurosurgeons performing surgeries
over this period and loss to follow-up of six patients.
Conclusion
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Clear Cells in Grade 3 ependymal tumors are found mainly in an adult population, with a predilection
for supratentorial parietal location. We observed worse progression-free and OS in the presence of clear
cells in comparison with classic AE. On univariate and multivariate analysis, age >55 years and
recurrence of disease were statistically significant factors for poor OS, with clear cells having a hazard
ratio of 1.8 times more on OS. The presence of disease in this part of the world – Pakistan and India
may follow a more aggressive course.
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